The past decade has seen an increasing interest in the early identification and treatment of obesity hypoventilation syndrome (OHS). This has largely arisen from a greater recognition that untreated OHS is associated with significantly higher levels of morbidity and mortality compared with obstructive sleep apnea (OSA) alone ([@bib1]). Individuals with OHS experience poorer quality of life, increased health resource use, and greater adverse socioeconomic impacts than equally obese eucapnic individuals ([@bib2], [@bib3]). In addition, more than 50% of those with OHS have echocardiographic evidence of pulmonary hypertension and left ventricular hypertrophy ([@bib4], [@bib5]). Positive airway pressure (PAP) remains the mainstay of therapy for OHS, aiming to correct sleep disordered breathing, reverse awake respiratory failure, and improve clinical outcomes. Both continuous (CPAP) and bilevel (BPAP) therapy have been used for this condition, with several randomized comparative trials finding no difference between therapies in terms of resolution of awake respiratory failure, quality of life, or treatment adherence ([@bib6]--[@bib8]). However, few studies have specifically examined the effect of PAP therapy on the resolution of cardiac dysfunction and pulmonary hypertension ([@bib5], [@bib9], [@bib10]).

The Pickwick project is a large, multicenter study undertaken by the Spanish Sleep Network evaluating the comparative effectiveness of PAP therapy in patients with stable ambulatory OHS.

During the initial phase of the study, 221 patients with OHS and severe OSA were randomly assigned to CPAP, BPAP, or a control group for 2 months ([@bib11]). Two-dimensional and Doppler echocardiograms were used to evaluate medium-term changes in cardiac structure and function with these interventions ([@bib5]). Only those allocated to BPAP showed an improvement in systolic pulmonary artery pressure (−3.4 mm Hg) and a reduction in left ventricular hypertrophy. Whether these differences between therapies would be sustained longer term remained unanswered. In this issue of the *Journal*, Masa and colleagues (pp. [586--597](10.1164/rccm.201906-1122OC)) provide data to address this question ([@bib12]). After 2 months of intervention, those who had been initially allocated to the control group were rerandomized to either the CPAP or BPAP treatment groups, with all patients followed for 3 years with annual echocardiograms. Both PAP groups experienced significant improvements in systolic pulmonary artery pressure and left ventricle diastolic dysfunction, with no between-group differences. Awake blood gases, blood pressure, and dyspnea also improved significantly and similarly in both groups. No significant longitudinal changes in left ventricular hypertrophy or ejection fraction were seen with either mode of PAP.

Although these are important and clinically relevant findings, a few issues need to be considered in interpreting the results. Right heart catheterization (the gold standard for evaluation of pulmonary hemodynamics) would have provided a more accurate assessment of pulmonary hypertension ([@bib13]), but would have been unrealistic in such a large study population during a prolonged follow-up period. However, without right heart catheterization, the exact mechanism or mechanisms responsible for pulmonary hypertension remains unclear. Nevertheless, the cause of pulmonary hypertension in an OHS population is likely to be multifactorial, resulting from increased pulmonary vascular resistance caused by hypoxia-induced vasoconstriction and/or elevated left atrial pressure resulting from left heart dysfunction ([@bib10], [@bib14]). Another limitation of the study was that echocardiographic assessment of both right ventricular and left ventricular functions were rather limited; for example, common parameters for right ventricular systolic function (such as fractional area change, S-wave, and tricuspid annular plane systolic excursion) were not assessed. The precision of echocardiographic measurements can also be challenging in morbidly obese patients. Other interventions such as changes in medications during the study period may have confounded the improvements seen in pulmonary hypertension. Because pulmonary hypertension is often a result of left ventricular diastolic dysfunction, alterations in the use of diuretics over the study period could have produced some of the changes in systolic pulmonary artery pressure reported.

So what are the major clinical insights this study provides? First, less than 10% of the patients were diagnosed with pulmonary hypertension before enrolment in this study, rising to more than 50% once a more thorough assessment was performed. This suggests that pulmonary hypertension, albeit generally mild to moderate, is both common and underrecognized in this population. Second, although the mean fall in systolic pulmonary artery pressure was around 6 mm Hg for both PAP groups, those with baseline pulmonary hypertension experienced a much greater mean fall of around 11 mm Hg, irrespective of the mode of PAP used. Furthermore, an improvement in 6-minute-walk distance was observed only in subjects with baseline pulmonary hypertension. This provides indirect evidence that mild to moderate pulmonary hypertension contributes to an exercise limitation in OHS. Third, improvements in pulmonary hypertension, similar to those of blood gases, may occur more slowly with CPAP therapy ([@bib6]), necessitating close monitoring during the first months of treatment with CPAP to ensure the patient is responding favorably to the intervention. Fourth, around a quarter of patients experienced residual pulmonary hypertension irrespective of the type of PAP used, which may adversely affect quality of life ([@bib14]). For those with significant residual pulmonary hypertension after optimized PAP, referral to an expert pulmonary hypertension center should be considered.

The findings from this study are important and should provide the clinician with greater assurance that long-term management of patients with stable OHS and coexistent OSA with CPAP therapy is safe, effective and not inferior to BPAP in the majority of cases ([@bib15]). Nevertheless, those individuals presenting with more severe respiratory failure, who are older or who have less severe OSA may still respond better to BPAP, highlighting the need for careful follow-up and considered clinical judgement. However, weight loss and reductions in sedentary behaviors should remain at the heart of our intervention strategies in this population.
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